Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05545501 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05545501 · ClinicalTrials.gov record · last posted 2026-08-19

Ketone Ester and Salt (KEAS) in Young Adults

Study acronym: KEAS
StatusRecruiting
PhaseNot applicable
Started2023-03-24
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs the ability of systemic blood vessels and the kidneys to control blood pressure, which contributes to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. There is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. However, limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could allow us to determine novel therapeutic targets to combat high salt.

Protocol amendment history 1 change detected by DataLookout

2026-08-20
notable
Primary completion pushed: 2027-08-31 → 2027-12-31
Trial Details
NCT Number NCT05545501
Lead Sponsor Indiana University
Collaborators: University of Utah, University of Missouri-Columbia
Conditions Salt; Excess, Hypertension
Enrollment 35 participants
Start Date 2023-03-24
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-19